Emisphere Technologies Inc (EMIS)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Emisphere Technologies Inc (EMIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012297
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Emisphere Technologies Inc (Emisphere) is a specialty pharmaceutical and drug delivery company. The company in partnership with global pharmaceutical companies develops novel oral formulations of existing injectable bio-pharmaceutical products, besides new chemical entities, using its Eligen technology. Its lead product Eligen B12, is the first and only once-daily oral prescription medical food approved in the US for treatment of vitamin b12 deficiency. The product is sold through a range of distributors, sellers, and other sources. Emisphere also uses its proprietary Eligen technology to produce novel oral formulations of therapeutic agents. The company’s product pipeline includes prescription drugs and medical food products that are being developed in partnership or internally. Emisphere is headquartered in Roseland, New Jersey, the US.

Emisphere Technologies Inc (EMIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Emisphere Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Novo Nordisk Enters into Licensing Agreement with Emisphere 10
Novo Nordisk Amends Licensing Agreement with Emisphere 12
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 13
Equity Offering 14
Emisphere Technologies Completes Private Placement Of Units For US$3.75 Million 14
Emisphere Technologies Issues Units To MHR In Private Placement For US$3.75 Million 15
Emisphere Technologies Inc – Key Competitors 16
Emisphere Technologies Inc – Key Employees 17
Emisphere Technologies Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
May 12, 2017: Emisphere Reports First Quarter 2017 Financial Results 19
Mar 29, 2017: Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results 20
Nov 14, 2016: Emisphere Reports Third Quarter 2016 Financial Results 23
Aug 15, 2016: Emisphere Reports Second Quarter 2016 Financial Results 26
May 16, 2016: Emisphere Reports First Quarter 2016 Financial Results 29
Mar 29, 2016: Emisphere Reports Fourth Quarter and Full Year 2015 Financial Results 31
Other Significant Developments 34
Dec 09, 2016: Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Emisphere Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Emisphere Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novo Nordisk Enters into Licensing Agreement with Emisphere 10
Novo Nordisk Amends Licensing Agreement with Emisphere 12
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 13
Emisphere Technologies Completes Private Placement Of Units For US$3.75 Million 14
Emisphere Technologies Issues Units To MHR In Private Placement For US$3.75 Million 15
Emisphere Technologies Inc, Key Competitors 16
Emisphere Technologies Inc, Key Employees 17

★海外企業調査レポート[Emisphere Technologies Inc (EMIS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qatar Fuel (WOQOD) Q.S.C. (QFLS):企業の財務・戦略的SWOT分析
    Qatar Fuel (WOQOD) Q.S.C. (QFLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Brown Advisory Inc:企業の戦略・SWOT・財務分析
    Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report Summary Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Shui On Land Limited:企業の戦略・SWOT・財務情報
    Shui On Land Limited - Strategy, SWOT and Corporate Finance Report Summary Shui On Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • FMT Aircraft Gate Support Systems AB:企業の戦略・SWOT・財務情報
    FMT Aircraft Gate Support Systems AB - Strategy, SWOT and Corporate Finance Report Summary FMT Aircraft Gate Support Systems AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …
  • OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析
    Summary Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used for the treatment of metabolic diseases, derm …
  • Faurecia S.A.:企業の戦略・SWOT・財務情報
    Faurecia S.A. - Strategy, SWOT and Corporate Finance Report Summary Faurecia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • DH Private Equity Partners:企業の戦略・SWOT・財務分析
    DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report Summary DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Aeras Global TB Vaccine Foundation Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines. The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinica …
  • CryoPort Inc (CYRX)-製薬・医療分野:企業M&A・提携分析
    Summary Cryoport Inc (Cryoport) is a provider of cold chain logistics solutions for temperature-sensitive biological materials to the life science industries. It offers liquid nitrogen dry vapor shippers with advanced logistics management platform called Cryoportal, which provides credentials relate …
  • Sasol Limited:企業の戦略・SWOT・財務情報
    Sasol Limited - Strategy, SWOT and Corporate Finance Report Summary Sasol Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • 220 Laboratories Inc.:企業の戦略・SWOT・財務情報
    220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report Summary 220 Laboratories Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hualan Biological Engineering Inc (002007):企業の財務・戦略的SWOT分析
    Summary Hualan Biological Engineering Inc (Hualan Biological) is a biopharmaceutical company that develops vaccines. The company conducts research, develops and produces plasma, vaccines and gene products. Its plasma products include surgical lyophilized fibrin sealant, human coagulation factor VIII …
  • BerGenBio ASA (BGBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary BerGenBio ASA (BerGenBio) is a clinical-stage biopharmaceutical company that develops drugs to treat multiple aggressive cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 is an AXL kinase inhibitor which …
  • GenSight Biologics SA (SIGHT):製薬・医療:M&Aディール及び事業提携情報
    Summary GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company’s product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It d …
  • Partner Reinsurance Asia Pte. Ltd.
    Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Daktronics Inc (DAKT):企業の財務・戦略的SWOT分析
    Daktronics Inc (DAKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • KCB Group Plc.:企業の戦略・SWOT・財務情報
    KCB Group Plc. - Strategy, SWOT and Corporate Finance Report Summary KCB Group Plc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Haisco Pharmaceutical Group Co Ltd (002653)-医療機器分野:企業M&A・提携分析
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations and bulk drugs. The company's product portfolio comprises injection for trace elements, compound vitamin, invert sugar, fat soluble …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆